Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Q Lacy

Showing results (131-140 of 142) with videos related to

Pageof 15
Sort By:
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
British Journal of Haematology|January 16, 2007
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosisE M Ocio, R F J Schop, B Gonzalez, et al.
Leukemia|December 2, 2016
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryE Muchtar, A Dispenzieri, S K Kumar, et al.
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Leukemia|July 27, 2016
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progressionW I Gonsalves, S V Rajkumar, A Dispenzieri, et al.
Blood Cancer Journal|December 8, 2021
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experienceI Vaxman, J Abeykoon, A Dispenzieri, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Blood Cancer Journal|February 18, 2017
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myelomaN Tandon, S V Rajkumar, B LaPlant, et al.
Leukemia|September 19, 2017
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chainsS Sidana, N Tandon, A Dispenzieri, et al.
Leukemia|June 29, 2017
Natural history of t(11;14) multiple myelomaA Lakshman, M Alhaj Moustafa, S V Rajkumar, et al.
Pageof 15

Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
British Journal of Haematology|January 16, 2007
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosisE M Ocio, R F J Schop, B Gonzalez, et al.
Leukemia|December 2, 2016
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryE Muchtar, A Dispenzieri, S K Kumar, et al.
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Leukemia|July 27, 2016
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progressionW I Gonsalves, S V Rajkumar, A Dispenzieri, et al.
Blood Cancer Journal|December 8, 2021
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experienceI Vaxman, J Abeykoon, A Dispenzieri, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Blood Cancer Journal|February 18, 2017
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myelomaN Tandon, S V Rajkumar, B LaPlant, et al.
Leukemia|September 19, 2017
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chainsS Sidana, N Tandon, A Dispenzieri, et al.
Leukemia|June 29, 2017
Natural history of t(11;14) multiple myelomaA Lakshman, M Alhaj Moustafa, S V Rajkumar, et al.
Pageof 15